CareersInvestor RelationsPress RoomCOVID-19
  1. Home
  2. Laboratory Diagnostics
  3. Assays by Diseases and Conditions
  4. Diabetes
  5. Diagnostic testing for diabetes and diabetes-related conditions

Tests for Diabetes and Its Related ConditionsWhy choose Siemens Healthineers?

Important diabetes tests

Tests that everyone with diabetes should receive

  • Hemoglobin A1c blood glucose test (recommended every 3–6 months)1
  • Lipid panel test for total cholesterol, HDL, LDL, and triglycerides (recommended once per year)1
  • Urine test to check kidney health (recommended once per year)1
  • Blood test to check heart health (recommended once per year)2
  • Liver function test (recommended once per year)1

Why get these tests?

Why should everyone with diabetes receive these tests?

Diabetes seldom occurs in isolation. A diabetes diagnosis is often accompanied by related conditions such as cardiovascular disease, kidney problems, foot and lower limb complications, nonalcoholic fatty liver disease (NAFLD), and hyperglycemia in pregnancy. 

With 45% of people with diabetes undiagnosed,3 or diabetes recognized only when life-threatening complications develop, testing is critical to diagnose and provide appropriate and timely care.

Infographic: Diabetes and its related conditions

45% of people with diabetes are undiagnosed or diabetes recognized when live-threatening complications develop. Testing is critical to provide timely care.

Diabetes and its related conditions

Download the Diabetes and Its Related Conditions infographic to understand the role of early detection and monitoring in achieving better patient outcomes.

Assay menu

The broad and expanding Atellica® Solution menu includes high-performing routine, esoteric, lipid, cardiac, kidney, and liver-related assays, making test consolidation on a single, automated platform easy and effective.

 

Routine and Esoteric Diabetes Assays

C-Peptide

      √

 

     √

 

 

      √

Fructosamine

 

     √

     √

       √*§

       √*§

 

Glucose

 

     √†

     √

       √

       √

     

HbA1c

 

     √

     √

       √**

       √**

 

Insulin

     √

 

     √

 

 

      √

Chemistry (Lipid) Assays

Cholesterol

     √†

     √

     √

     √

HDL Cholesterol

     √

     √

     √

     √

LDL Cholesterol

     √

     √

     √

     √

Triglycerides

     √†

     √

     √

     √

Cardiac Assays

BNP

     √

     √

     √‡

     √§

CKMB Mass

     √

     √

     √

     √

     √§

CKMB Isoenzyme

     √

     √

D-Dimer

     √§

High-Sensitivity CRP

     √

     √

     √

     √

     √

High-Sensitivity Troponin I

     √

     √

     √

     √

Myoglobin

     √

     √

     √

     √

     √

NT-proBNP

     √§

     √§

     √

     √

     √§

Troponin I

     √

Kidney Assays

β2 Microglobulin

     √

     √

     √*§

     √

     √

Creatinine

     √†

     √

     √

     √

Creatinine, Enzymatic

     √

     √

     √

     √

Cystatin C

     √

     √

     √

Urinary Albumin/Microalbumin

     √

     √

     √

     √

Urea Nitrogen

     

     √†

     √

     √

     √

Liver Assays

Enhanced Liver Fibrosis (ELF™) Test

     √

     √

*Alliance Application manufactured by third party, distributed by Siemens Healthcare Diagnostics.
† Also available in concentrated version.
‡ Available for sale only in Japan.
§ Not available for sale in the U.S.
A doctor discussing diabetes testing with her patients

Webinar: Diabetes—beyond HbA1c

Webinar: Diabetes—beyond HbA1c

Join Dr. Youssef Maakaroun, MD, as he discusses the various conditions associated with diabetes and how innovative assays can help optimize management of diabetes patients and route them for proper care.

A nurse wearing pink scrubs welcomes an older male patient in the waiting room holding his chart

MLO article: Importance of HbA1c testing for diabetes diagnosis and management post COVID-19 infection

Importance of hemoglobin A1c testing for diabetes diagnosis and management post-COVID-19 infection (2023)

MLO: Early identification and treatment of the disease can improve health outcomes by avoiding or delaying long-term diabetic complications.

Five-minute video: NAFLD/NASH prevalence in type 2 diabetes patients and use of noninvasive tests

NAFLD/NASH prevalence in type 2 diabetes patients and use of noninvasive tests

Watch this 5-minute video where Dr. Scott D. Isaacs, an endocrinologist and obesity medicine specialist, discusses the risk and prevalence of NAFLD and NASH in patients with type 2 diabetes and his experience and recommendations in managing these patients, including the use of noninvasive tests.

Looking for point-of-care (POC) diabetes testing solutions? Get information on Siemens Healthineers POC diabetes testing solutions.

The products/features (mentioned herein) are not commercially available in all countries. Due to regulatory reasons, their future availability cannot be guaranteed. Please contact your local Siemens Healthineers organization for further details.